Results 131 to 140 of about 39,467 (264)

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis

British Journal of Haematology, Volume 207, Issue 4, Page 1388-1396, October 2025.
Durable responses based on modified Valent, IWG‐MRT‐ECNM and PPR criteria were predominantly dose‐independent, making dose adjustments due to better tolerability more practicable in daily routine. Gradual tapering of midostaurin, prophylactic treatment with antihistamines and corticosteroids and timely initiation of subsequent therapy can prevent a ...
Johannes Lübke, Nicole Naumann, Timo Brand, Laurenz Steiner, Roland Repp, Georgia Metzgeroth, Alice Fabarius, Wolf‐Karsten Hofmann, Deepti H. Radia, Andreas Reiter, Juliana Schwaab   +10 more
wiley   +1 more source

Prevalence and clinical significance of sarcopenia in patients with chronic myeloproliferative neoplasms: epidemiology, diagnosis, and intervention strategies

КардиоСоматика
Chronic myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic disorders that predominantly affect older patients. These conditions are associated with increased risk of numerous complications.
Adelina G. Garifullina, Bulat A. Bakirov, Gulnaz H. Lasynova, Evgeny O. Goldyrev, Dmitry A. Kudlay   +4 more
doaj   +1 more source

Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia: Implications for Treatment Strategy

Case Reports in Hematology, 2013
Myeloproliferative disorders are variable disorders, based on the genetic abnormality present and the cell line progenitors that are affected. In this case, we discuss a novel gene translocation in the subset of PDGFRB mutations, first seen with ...
Joel D. Provenzano, J. Phillip Kuebler
doaj   +1 more source

Covert Brain Infarcts in Patients with Philadelphia Chromosome-Negative Myeloproliferative Disorders. [PDF]

J Clin Med, 2021
Kuznetsova PI, Raskurazhev AA, Konovalov RN, Krotenkova MV, Chechetkin AO, Lagoda OV, Melikhyan AL, Tanashyan MM.   +7 more
europepmc   +1 more source

Refractory anaemia terminating in a combined lymphoproliferative and myeloproliferative disorder. [PDF]

, 1985
Lionello Camba, M V Joyner
openalex   +1 more source

Second‐ and Third‐Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML—A Population‐Based Study

European Journal of Haematology, Volume 115, Issue 4, Page 423-432, October 2025.
ABSTRACT Refractory acute myeloblastic leukemia (AML) is poorly studied. In this study, we characterized primary refractory AML and investigated treatment and outcome in a population‐based setting. Based on all AML patients receiving intensive induction therapy at 12 Swedish hospitals from 2011 to 2018 (N = 1221), we identified 306 patients that failed
Markus Liew‐Littorin, Linn Deleskog‐Spångberg, Stefan Deneberg, Judit Janosi, Vladimir Lazarevic, Gustav Nilsson, Aristea Papageorgiou, Anna Robelius, Lovisa Vennström, Gunnar Juliusson, Bertil Uggla, Martin Höglund, Sören Lehmann   +12 more
wiley   +1 more source

Myeloproliferative Disorders [PDF]

Clinical Medicine, 2005
openaire   +3 more sources

Ischemic Stroke in a Young Man: Unraveling the Domain of Myeloproliferative Disorders. [PDF]

Cureus, 2021
Hamid MAB, Sehbai AS, Tariq S.
europepmc   +1 more source

Neurological manifestations of chronic graft versus host disease

Internal Medicine Journal, Volume 55, Issue 10, Page 1639-1646, October 2025.
Abstract Introduction Allogeneic haemopoietic stem cell transplant (allo‐HSCT) is an established therapy for many malignant and non‐malignant conditions, with an increasing number of uses and indications in recent decades. Complications including graft versus host disease (GvHD) carry significant morbidity and mortality.
Tal Koren, Alice Kwok, William Stevenson, Kate Ahmad, Joseph Nogajski, John Parratt, Ian Kerridge, Karl Ng   +7 more
wiley   +1 more source

Differentiation of blast cells from a Down's syndrome patient with transient myeloproliferative disorder [PDF]

, 1987
J Suda, M Eguchi, Y Akiyama, Y Iwama, T Furukawa, Y Sato, Y Miura, T Suda, M Saito   +8 more
openalex   +1 more source